Drug-induced hepatic disorders. Incidence, management and avoidance

Area of Science:

• Hepatology
• Clinical Pharmacology
• Toxicology

Background:

• Drug-induced liver injury (DILI) is a significant cause of hospital admission, accounting for 2-3% of adverse drug reactions.
• Over 800 drugs are associated with DILI, presenting with nonspecific symptoms and a variable latency period.
• DILI can mimic virtually any form of liver disease, complicating diagnosis.

Purpose of the Study:

• To review the clinical presentation, diagnosis, and management of drug-induced liver injury.
• To emphasize the importance of a high index of suspicion and thorough drug history in DILI detection.
• To provide guidance on cautious drug use in specific patient populations and warn against hepatotoxic drug abuse.

Main Methods:

• Review of literature on drug-induced liver injury.
• Analysis of clinical characteristics, diagnostic challenges, and treatment strategies for DILI.
• Discussion of preventative measures and patient counseling regarding hepatotoxic medications.

Main Results:

• DILI has a serious prognosis and nonspecific clinical features, making diagnosis challenging.
• Exclusion of other liver diseases and detailed drug history are key to identifying DILI.
• Treatment involves drug withdrawal, specific antidotes (e.g., acetylcysteine for paracetamol), and liver transplantation in severe cases.

Conclusions:

• Prompt recognition and management of DILI are essential for improving patient outcomes.
• Adherence to drug guidelines, cautious prescribing in vulnerable patients, and public awareness are vital for preventing DILI.
• Hepatotoxicity necessitates careful consideration of drug risks versus benefits, especially with common agents like paracetamol.